At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study of N-acetylcysteine in Patients With Transplant-Associated Thrombotic Microangiopathy
In Brief
A Phase 3 clinical trial evaluating N-Acetylcysteine and Placebo Oral Tablet for Thrombotic Microangiopathies and Hematologic Diseases. Completed, enrolled 170 participants across 1 site.
Detailed Summary
HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement of other organs. N-Acetylcysteine (NAC) is a small, simple molecule that began as a generic drug almost 40 years ago. It has since been approved by the FDA for many indications. The investigators conducted an prospective clinical trial to evaluate the safety and efficiency of NAC in patients with TA-TMA.
Study Details
Timeline
Interventions
50mg/Kg.d, oral
50mg/Kg.d, oral